Australia's EBR Systems jumps on FDA nod to use pacemakers in trial

EBR Systems

14/03/2022 03:24

** Shares of EBR Systems Inc  EBR.AX  rise as much as 8.5%
to A$0.705, hitting their highest since Feb 28
    ** The medical device maker says the U.S. Food & Drug
Administration (FDA) has agreed for EBR to include leadless
pacemakers as a co-implant in its SOLVE-CRT IDE clinical trial
 urn:newsml:reuters.com:*:nASX52P24N
    ** Says study will be able to include commercially available
leadless pacemakers as co-implants for the WiSE CRT System to
deliver cardiac resynchronisation therapy for eligible patients
    ** Funding requirements, key endpoints, and timing of the
SOLVE-CRT trial will not be affected by this development with
enrolment for interim analysis still expected to complete by H1
2022 - EBR
    ** Stock down 29.7% YTD, as of last close
    

 (Reporting by Arundhati Dutta in Bengaluru)
 ((Arundhati.Dutta@thomsonreuters.com;))